Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women

•Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy.•Its prolonged action makes patient selection important, as the implants cannot easily be removed.•In women with an intact uterus, the continuation of progestin therapy after cessation of impl...

Full description

Saved in:
Bibliographic Details
Published in:Maturitas Vol. 94; pp. 84 - 86
Main Authors: Wheatley, Shaday, Bell, Robin J., Stuckey, Bronwyn G.A., Robinson, Penelope J., Davis, Susan R.
Format: Journal Article
Language:English
Published: Ireland Elsevier B.V 01.12.2016
Subjects:
Clinical Audit
Drug Implants
Estradiol - administration & dosage
Estradiol - therapeutic use
Estrogen Replacement Therapy - methods
Female
Hormone implant
Humans
Internal Medicine
Menopausal hormone therapy
Middle Aged
Obstetrics and Gynecology
Oestradiol
Postmenopause
Retrospective Studies
Time Factors
Oestradiol
Hormone implant
Menopausal hormone therapy
ISSN:0378-5122, 1873-4111, 1873-4111
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Estrapel is an oestradiol implant that provides a non-oral treatment option for menopausal hormone therapy.•Its prolonged action makes patient selection important, as the implants cannot easily be removed.•In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative. We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49–875), with an estimated median time to return to baseline of 311days (range 108–1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5122
1873-4111
1873-4111
DOI:10.1016/j.maturitas.2016.09.008